AstraZeneca, Merck Get CHMP Positive Opinions for Expanded Lynparza Use
September 21 2020 - 10:42AM
Dow Jones News
By Colin Kellaher
AstraZeneca PLC and Merck & Co. Monday said the European
Medicines Agency's Committee for Medicinal Products for Human Use
recommended approval of two additional indications for the cancer
drug Lynparza.
The drugmakers said one recommendation covers Lynparza as
monotherapy for the treatment of adults with metastatic
castration-resistant prostate cancer and BRCA1/2 mutations who have
progressed following a prior therapy that included a new hormonal
agent.
The second recommendation covers Lynparza as a first-line
maintenance treatment in combination with bevacizumab for
HRD-positive advanced ovarian cancer.
The indications now await approval from the European Commission,
which generally follows the CHMP's recommendations.
AstraZeneca and Merck in 2017 formed a collaboration to
co-develop and co-commercialize Lynparza for multiple cancer
types.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 21, 2020 10:27 ET (14:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Mar 2024 to Apr 2024
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Apr 2023 to Apr 2024
